Canan ULUOĞLU, Aynur OĞUZ, Gürsel BİBEROĞLU, Fatih Süheyl EZGÜ, Alev HASANOĞLU, Özenç TİMLİOĞLU

Methotrexate related acute hepatotoxicity

Amaç: Metotreksat, non-Hodgkin lenforma tedavisinde kullanılan en etkili ajanlardan biridir. Metotreksata bağlı hepatotoksisite daha önceki çalışmalarda bildirilmiştir. Bu çalışmada non-Nodgin Lenfomalı 10 çocuk hastada orta doz (1g/m2) metotreksata bağlı oluşabilecek hepatotoksisite incelenmiştir. Metod: Çalışmaya Burkitt Lenfomalı, 3-10 yaşları arasındaki 10 çocuk hasta dahil edilmiştir. Tedavide Modifiye BFM-90 B-hücre Lenfoma Protokolü kullanılmıştır. Bulgular: Serum metotreksat düzeyleri ile karaciğer toksisitesi arasında anlamlı korelasyon saptanmamıştır. Geçici transaminaz yüksekliği ve hafif derecede hepatomegaly dışında bulguya rastlanmamıştır. Transaminaz düzeyleri 2-11 gün sonar normale dönmüştür. Sonuç: Histlojik olarak karaciğer toksisitesi kanıtlanmadıkça metotreksat dozlarında indirime gidilmemelidir.

Metotreksata bağlı akut hepatotoksisite

Purpose: Methotrexate is one of the most effective chemotherapeutic agents used to treat non-Hodgkin lymphoma. Hepatotoxicity due to methotrexate was reported in many studies. In this study, hepatotoxicity caused by intermediate dose (lg/m3) methotrexate in 10 patients with non-Hodgkin lymphoma was investigated. Method: Ten patients between 3 and 13 years of age with Burkitt's Lymphoma, were investigated. Modified BFM-90 B-cell Lymphoma Protocol was used in the treatment. Results: No correlation was found between serum methotrexate levels and hepatic toxicity; and no other signs of hepatotoxicity were detected except temporary transaminase elevations and mild hepatomegaly. Transaminase levels returned to normal after about 2-11 days. Conclusion: Dose reductions in methotrexate do not seem warranted if serious liver damage has not been confirmed by histology.

PDF

___

1. Cortelazzo S, Rambaldi A, Rossi A, Oldani E, Ghielmini M, Benedetti F, Tarella C, Zaglio F, Vitolo U, Di Nicola M, Pogliani E, Cavalli F, Gianni AM, Barbui T. Intensification of salvage treatment with high-dose sequential chemotherapy improves the outcome of patients with refractory or relapsed aggressive non- Hodgkin's lymphoma. Br J Haematol 2001; 114: 333-341.
2. Macdonald JS. Cancer chemotherapy and the liver. Clin Liver Dis 1998, 2: 631-642.
3. Zachariae H, Sogaard H. Methotrexate-induced liver chirrosis. A follow-up, Dermatologica 1987; 175: 178-182.
4. Wang Y-M, Fujimato T. Clinical pharmacokinetics of methotrexate in children. Clin Pharmacokinet 1984; 9:335-348.
5. Weber BL, Tanyer G. Transient acute hepatotoxicity of high dose methotrexate therapy during childhood. NCI Monogr 1987; 5: 207-212.
6. Najjar TAO, Alfawas IM. Pharmacokinetics of methotrexate in children with acute lymphocytic leukemia. Chemotherapy 1993; 39: 242-247.
7. Assadullahi TP, Dağlı E. High performance liquid chromatography method for serum methotrexate level in children with severe steroid dependent asthma. J Chromatogr 1991; 565: 349-356.
8. van den Bongard HJ, Mathjt RA, Boogerd W, Schornagel JH, Soesan M, Schellens JH, Beijnen JH. Successful rescue with leucoyorin and thymidine in a patient with high-dose methotrexate induced acute renal failure. Cancer Chemother Pharmacol 2001; 47: 537-540.
9. Schmiegelow K, Schroder H. Maintenance chemotherapy for childhood acute lymphoblastic leukemia: relation of bone-marrow and hepatotoxicity to the concentration of MTX in erythrocytes. Cancer Chemother and Pharmacol 1989; 25: 65-69.
10. Kaito K, Katayama T. Fulminant hepatic failure induced by intermediate dose methotrexate in a case of non- Hodgkin's lymphoma. Jap J Clin Hematol 1990; 31: 1862- 1867.
11. Locasciulle A, Mura R. High dose methotrexate administration and acute liver damage in children treated for acute lymphoblastic leukemia. Hematologica 1992; 77: 49-53.
12. Schmiegelow K, Pulczynska M. Prognostic significance of hepatotoxicity during maintenance chemotherapy for childhood acute lymphoblastic leukemia. Br J Cancer 1990; 61: 767-772.